Alkermes announces Anne C. Whitaker's appointment to board via press release
The company confirmed the September 14 board appointment in a September 16 statement that included executive comments and details on Whitaker's background.
SEC filing
Latest
24 stories
Yesterday
Monday, September 28
HUTCHMED begins global Phase Ia trial of HMPL-A830 in solid tumors after GSK licensing deal
Thursday, September 24
New Phase Ib myeloma study registered; GSK-linked FTD trial terminated, BRCA study posted
Friday, September 18
GSK's IPF drug GSK3915393 fails Phase 2 on futility; expanded access opens for velzatinib in GIST
Wednesday, September 16
Tuesday, September 15
GSK to acquire trispecific T cell engager for multiple myeloma from Chimagen
GSK will pay up to $750 million for a Chimagen asset expected to begin phase I trials in 2027, targeting multiple myeloma.
SEC filing
Thursday, September 10
Japan clears prefilled syringe version of GSK's Shingrix
MHLW authorized a ready-to-use presentation of the shingles vaccine, replacing the two-vial format that required manual mixing.
SEC filing
Friday, September 4
GSK registers Phase 3 trials for mRNA flu vaccine and prostate cancer ADC Ris-Rez
Thursday, September 3
HUTCHMED licenses HMPL-A830 to GSK; source cites both $1.295B and $1.185B totals
HUTCHMED will get $110 million upfront as GSK takes global rights outside Greater China to the KRAS-EGFR conjugate HMPL-A830, with milestone figures stated differently across the filing.
SEC filing
Thursday, August 27
GSK posts results for 2021 COVID-19 SAM vaccine trial; advances four Phase 3 respiratory studies
Wednesday, August 26
NIAID-led IMPAACT 2026 pharmacokinetic study terminated early, results posted
Monday, August 24
Japan approves GSK's Hibsago as first functional cure for chronic hepatitis B
MHLW cleared bepirovirsen on August 24, 2026, marking the drug's first global approval, backed by Phase III B-Well data.
SEC filing
Friday, August 21
GSK posts propellant trial results; recruits for three Phase 3 felcorekibart studies
Thursday, August 20
Lilly registers Phase 3 depression trial; posts results for two psoriasis and oncology studies
Thursday, August 6
GSK-linked trials: six new registrations this week, all not yet recruiting
Tuesday, August 4
iBio names endocrinologist Molly Carr as chief medical officer
The clinical-stage biotech hired the former Eli Lilly insulin executive effective July 31, 2026, and granted her 430,000 inducement stock options.
SEC filing
Tuesday, July 28
Hansoh's Ris-Rez hits PFS endpoint in second phase III osteosarcoma trial
GSK's licensor Hansoh Pharma reported that ARTEMIS-011 met its primary endpoint in relapsed osteosarcoma, adding to prior positive lung cancer data.
SEC filing
Thursday, July 23
Summit reports Q2 2026 results as HARMONi OS data hold up in western patients
Summit Therapeutics posted $690.7 million in cash at quarter end and highlighted updated HARMONi survival data ahead of a November 14, 2026 FDA decision on ivonescimab.
SEC filing (2)
Wednesday, July 22
GSK wins US approval for Jideytro in previously treated ROS1-positive lung cancer
The FDA cleared the ROS1 inhibitor ahead of schedule, marking GSK's first lung cancer approval and its first product from the Nuvalent acquisition.
SEC filing
Montefiore registers Phase 1 trial pairing Talquetamab with belantamab mafodotin in myeloma
Friday, July 17
GSK halts camlipixant development in refractory chronic cough after mixed phase III results
CALM-1 hit its primary endpoint but CALM-2 did not, and GSK said the combined data will not change patient care.
SEC filing (2)
GSK CMV vaccine trial posts results; six new studies span cardiovascular, MASH, CRSwNP
Wednesday, July 15
GSK completes acquisition of Nuvalent for $10.6 billion
The deal adds three lung cancer assets, including two FDA-reviewed drugs, to GSK's oncology pipeline.
SEC filing